Prospects of magnetic resonance spectroscopy in mouse models of alzheimer's disease

Current Medical Imaging Reviews

Volumn 7, Issue 1, 2011, Pages 80-87

  Kara, Firat ^a   Braakman, Niels ^a   van Buchem, Mark A ^b   de Groot, Huub J M ^a   Alia, A ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Alzheimer's disease; Magnetic resonance spectroscopy; Transgenic mouse models

Indexed keywords

AMYLOID PRECURSOR PROTEIN; CELECOXIB; DONEPEZIL; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; IBUPROFEN; PRESENILIN 2; TAU PROTEIN; TAURINE;

ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; DRUG EFFECT; HIPPOCAMPUS; HUMAN; IN VIVO STUDY; LONGITUDINAL STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTON NUCLEAR MAGNETIC RESONANCE;

EID: 79955649995     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340511794653469     Document Type: Article

References (65)

1. Bartha R, Smith M, Rupsingh R, Rylett J, Wells JL, Borrie MJ. High field (1)H MRS of the hippocampus after donepezil treatment in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 786-93.
2. Choi IY, Lee SP, Guilfoyle DN, Helpern JA. In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models. Neurol Res 2003; 28: 987-1001.
3. Jessen F, Block W, Traber F, et al. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001; 57: 930-2.
4. Krishnan KRR, Cecil CH, Murali DM, et al. Randomized, placebocontrolled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160: 2003-11.
5. Khachaturian ZS, Emr M. Research workshop on the diagnosis of Alzheimer-disease. Neurobiol Aging 1984; 5: 161-2.
6. Choi JK, Dedeoglu A, Jenkins BG. Application of MRS to mouse models of neurodegenerative illness. NMR Biomed 2007; 20: 216-37.
7. Soher BJ, Doraiswamy PM, Charles HC. A review of (1)H MR spectroscopy findings in Alzheimer's disease. Neuroimaging Clin N Am 2005; 15: 847-52.
8. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science, 1993; 262: 689-95.
9. Fonnum F. Glutamate: a neurotransmitter in mammalian brain. J Neurochem 1984; 42: 1-11.
10. Arnold DL, Matthews PM, Francis G, Antel J. Proton magnetic resonance spectroscopy of human brain in vivo in the evaluation of multiple sclerosis: assessment of the load of disease. Magn Reson Med 1990; 14: 154-9.
11. Miller BL. A Review of Chemical Issues in H-1-NMR Spectroscopy- N-Acetyl-L-Aspartate, Creatine and Choline. NMR Biomed 1991; 4: 47-52.
12. Ross B, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001; 265(2): 54-84.
13. Kantarci K. (1)H Magnetic resonance spectroscopy in dementia. Br J Radiol 2007; 80: S146-52.
14. Mandal PK. Magnetic resonance spectroscopy (MRS) and its application in Alzheimer's disease. Concept Magn Res 2007; 30: 40-64.
15. Moore CM, Frederick BB, Renshaw PF. Brain biochemistry using magnetic resonance spectroscopy: relevance to psychiatric illness in the elderly. J Geriatr Psychiatry Neurol 1999; 12: 107-17.
16. Pettegrew JW, Klunk WE, Panchalingam K, McClure RJ, Stanley JA. Molecular insights into neurodevelopmental and neurodegenerative diseases. Brain Res Bull 2000; 53: 455-69.
17. Pettergrew JW, Moossy J, Withers G, McKeag D, Panchalingam K. (31)P nuclear magnetic resonance study of the brain in Alzheimer's disease. J Neuropathol Exp Neurol 1988; 47: 235-48.
18. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology 2001; 56; 592-8.
19. Cuénnod CA, Kaplan DB, Michot JL, et al. Phospholipid abnormalities in early Alzheimer's disease. In vivo phosphorus 31 magnetic resonance spectroscopy. Arch Neurol 1995; 52: 89-94.
20. Forlenza OV, Wacker P, Nunes PV, et al. Reduced phospholipid breakdown in Alzheimer's brain: a (31)P spectroscopy study. Psychopharmacology 2005; 180: 359-65.
21. Pettegrew JW. Molecular insights into Alzheimer's disease. Ann N Y Acad Sci 1989; 568: 5-28.
22. Pettegrew JW, Klunk WE, Kanal E, Panchalingam K, McClure RJ. Changes in brain membrane phospholipid and high-energy phosphate metabolism precede dementia. Neurobiol Aging 1995; 16(6): 973-5.
23. Pettegrew JW, Panchalingam K, Klunk WE, McClure RJ, Muenz LR. Alterations of cerebral metabolism in probable Alzheimer's disease: a preliminary study. Neurobiol Aging 1994; 15(1): 117-32.
24. Pettegrew JW, Panchalingam K, Moossy J, Martinez J, Rao G, Boller F. Correlation of P-31 magnetic resonance spectroscopy and morphologic findings in Alzheimer's disease. Arch Neurol 1988; 45: 1093-6.
25. Brown GG, Levine SR, Gorell JM, et al. In vivo (31)P NMR Profiles of Alzheimer's disease and multiple subcortical infarct dementia. Neurology 1989; 39: 1423-7.
26. Gonzalez RG, Guimaraes AR, Moore GJ, et al. Quantitative in vivo 31P magnetic resonance spectroscopy of Alzheimer's disesase. Alzheimer Dis Assoc Discord 1996; 10(1): 46-52.
27. Mecheri G, Marie-Cardine M, Sappey-Marinier, et al. In vivo hippocampal (31)P NMR metabolites is Alzheimer's disease and ageing. Eur Psychiatry 1997; 12(3): 140-8.
28. Smith CD, Pettigrew LC, Avison MJ, et al. Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. Ann Neurol 1995; 38: 194-201.
29. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999; 12(7): 413-39.
30. Adalsteinsson E, Sullivan EV, Kleinhans N, Spielman DM, Pfefferbaum A. Longitudinal decline of the neuronal marker N-acetyl aspartate in Alzheimer's disease. Lancet 2000; 355: 1696-7.
31. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology 1997; 203: 829-36.
32. Kantarci K, Weigand SD, Petersen RC, et al. Longitudinal (1)H MRS changes in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2007; 28: 1330-9.
33. Muskulus M, Scheenstra AEH, Braakman N, et al. Prospects for early detection of Alzheimer's disease from serial MR images in transgenic mouse models. Curr Alzheimer Res 2009; 6: 503-18.
34. Dedeoglu A, Choi JK, Cormier K, Kowall NW, Jenkins BG. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 2004; 1012: 60-5.
35. von Kienlin M, Kunnecke B, Metzger F, et al. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis 2005; 18: 32-9.
36. Marjanska M, Curran GL, Wengenack TM, et al. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci USA 2005; 102: 11906-10.
37. Woo DC, Lee SH, Lee DW, et al. Regional metabolic alteration of Alzheimer's disease in mouse brain expressing mutant human APPPS1 by (1)H HR-MAS. Behav Brain Res 2010; 211(1): 125-31.
38. Oberg J, Spenger C, Wang FH, et al. Age related changes in brain metabolites observed by (1)H MRS in APP/PS1 mice. Neurobiol Aging 2008; 29: 1423-33.
39. Chen SQ, Wang PJ, Ten GJ, Zhan W, Li MH, Zang FC. Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement Geriatr Cogn Disord 2009; 28: 558-66.
40. Jack CR, Wengenack TM, Reyes DA, et al. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J Neurosci 2005; 25: 10041-8.
41. Vanhoutte G, Dewachter I, Borghgraef P, Van Leuven F, Van der Linden A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn Reson Med 2005; 53: 607-13.
42. Braakman N, Matysik J, van Duinen SG, et al. Longitudinal assessment of Alzheimer's beta-amyloid plaque development in transgenic mice monitored by in vivo magnetic resonance microimaging. J Magn Reson Imaging 2006; 24: 530-6.
43. Braakman N, Matysik J, de Groot HJM, Schliebs R, Alia A. Correlation between neurochemical changes and development of Alzheimer's plaques with age monitored by in vivo high resolution magnetic resonance microimaging and spectroscopy. Mag Reson Med 2008; 16: 257.
44. Choi JK, Jenkins BG, Carreras I, et al. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp Neurol 2010; 223(2): 377-84.
45. Westman E, Spenger C, Oberg J, Reyer H, Pahnke J, Wahlund LO. In vivo H-1-magnetic resonance spectroscopy can detect metabolic changes in APP/PS1 mice after donepezil treatment. BMC Neurosci 2009; 10: 33.
46. Boska MD, Lewis TB, Destache CJ, et al. Quantitative H-1 magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease. J Neurosci 2005; 25: 1691-700.
47. Oz G, Nelson CD, Koski DM, et al. Noninvasive detection of presymptomatic and progressive neurodegeneration in a mouse model of spinocerebellar ataxia type 1. J Neurosci 2010; 30(10): 3831-8.
48. Tsang TA, Woodman B, McLoughlin GA, et al. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS H-1 NMR spectroscopy. J Proteome Res 2006; 5: 483-92.
49. Braakman N, Oerther T, de Groot HJM, Alia A. High resolution localized two-dimensional MR spectroscopy in mouse brain in vivo. Magn Reson Med 2008; 60: 449-56.
50. Thomas MA, Yue K, Binesh N, et al. Localized two-dimensional shift correlated MR spectroscopy of human brain. Magn Reson Med 2001; 46: 58-67.
51. Binesh N, Yue K, Fairbanks L, Thomas MA. Reproducibility of localized 2D correlated MR spectroscopy. Magn Reson Med 2002; 48: 942-8.
52. Thomas MA, Hattori N, Umeda M, Sawada T, Naruse S. Evaluation of two-dimensional L-COSY and PRESS using a 3 T MRI scanner: from phantoms to human brain in vivo. NMR Biomed 2003; 16: 245-51.
53. Ross AJ, Sachdev PS. Magnetic resonance spectroscopy in cognitive research. Brain Res Rev 2004; 44: 83-102.
54. Frangou S, Williams SCR. Magnetic resonance spectroscopy in psychiatry: Basic principles and applications. Br Med Bull 1996; 52: 474-85.
55. Ross B, Lin A, Harris K, Bhattacharya P, Schweinsburg B. Clinical experience with (13)C MRS in vivo. NMR Biomed 2003; 16: 358-69.
56. Shen J, Petersen KF, Behar KL, et al. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc Natl Acad Sci USA 1999; 96(14): 8235-40.
57. Miller BL, Moats RA, Shonk T, Ernst T, Woolley S, Ross BD. Alzheimer-Disease - Depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993; 187: 433-7.
58. Moats RA, Ernst T, Shonk TK, Ross BD. Abnormal cerebral metabolite concentrations in patients with probable Alzheimerdisease. Magn Reson Med 1994; 32: 110-5.
59. Shonk TK, Moats RA, Gifford P, et al. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995; 195: 65-72.
60. Kantarci K, Jack CR Jr, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A (1)H MRS study. Neurology, 2000; 55: 210-17.
61. Antuono PG, Jones JL, Wang Y, Li SJ. Decreased glutamate plus glutamine in Alzheimer's disease detected in vivo with H-1-MRS at 0.5T. Neurology 2001; 56: 737-42.
62. Dixon RM, Bradley KM, Budge MM, Styles P, Smith AD. Longitudinal quantitative proton magnetic resonance spectroscopy of the hippocampus in Alzheimer's disease. Brain 2002; 125: 2332-41.
63. Ackl N, Ising M, Schreiber YA, Atiya M, Sonntag A, Auer DP. Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2005; 384: 23-8.
64. Wang ZQ, Zhao C, Yu L, Zhou WD, Li KC. Regional metabolic changes in the hippocampus and posterior cingulate area detectedwith 3-Tesla magnetic resonance spectroscopy in patients with mild cognitive Impairment and Alzheimer disease. Acta radiol 2009; 50: 312-19.
65. Wang T, Xiao SF, Li X, et al. Hydrogen proton MR spectroscopy of posterior portion cingulate gyrus of patients with Alzheimer's disease: a case control study. Zhonghua Yi Xue Za Zhi 2009; 89: 37-40.